Gilead Sciences, Inc. (GILD)

Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $206.55B
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Latest financial period: September 30, 2026
Filed with the SEC: October 30, 2026
Estimated earnings date: Not available
Profit #1108 of 1422 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROIC | 4.1% | 2.5% | 22.5% | 16.2% |
Growth #578 of 1422 companies
Payout #849 of 1422 companies
Safety #914 of 1422 companies
Price #903 of 1422 companies